• Deccan Chronicle
  • Andhra Bhoomi
  • Asian Age
  • ePaper
  •  Auto Refresh
Home

ePaper
Last Updated:07:40 AM IST | Thursday, Aug 11, 2022
  • Home
  • Politics, Plan And Policy
  • Markets
  • Companies
  • Economy
  • In Other News
  • Autos
  • Just In
Menu
  • Home
  • Politics, Plan And Policy
  • Markets
  • Companies
  • Economy
  • In Other News
  • Autos
  • Just In
Home > Companies > Valsartan impurities under investigation
Companies
Valsartan impurities under investigation
Archak Sengupta
By  
  , Published : Sep 20, 2019, 1:16 am IST | Updated : Sep 20, 2019, 1:16 am IST

Valsartan, which is used to treat blood pressure and heart failure, is under inspection for carcinogenic impurities.

With several lots of the drugs voluntarily recalled by multiple drug companies due to the
With several lots of the drugs voluntarily recalled by multiple drug companies due to the "presence of traces of impurity" in the US market, the move will be eagerly watched by all Indian pharma firms. (Representational Image)

Hyderabad: The Drug Controller General of India (DCGI) on Thursday confirmed that the drug, Valsartan, which is used to treat blood pressure and heart failure, is under inspection for carcinogenic impurities.

With several lots of the drugs voluntarily recalled by multiple drug companies due to the "presence of traces of impurity" in the US market, the move will be eagerly watched by all Indian pharma firms.

Speaking on the sidelines of an annual event organised by Pharmaceut-ical Export Promotion Council of India (Pharmexcil) in Hydera-bad, V.G. Somani said, "That (the carcinogenic impurities) was a batch specific phenomena.

We are looking at it and we are investigating it... And we will take appropriate decision on whether to accept it as a risk, whether to take some action on prescribing the product or to ban the product."

He said the Central Drugs Standard Control Organisation was carrying out the investigation. However, the pharma firms can breathe easy as Mr Somani said the impurities were not found during the initial approval process of the product.

end-of
Tags: 
drug controller general of india (dcgi), valsartan, carcinogenic impurities
Location: 
India, Telangana, Hyderabad
Latest From Companies
HUL CMD Sanjiv Mehta said the results show that the long-term structural opportunity of FMCG in India remains intact.

HUL Q1 net profit rises 5.7 pc to Rs 1,897 crore

The management of Radar has built and exited 3 different businesses themselves which helps the sensitise first time and even veteran entrepreneurs.

Radar India advisors scales a new high

The top seven cities of Delhi, Mumbai, Kolkata, Chennai, Hyderabad, Pune and Bengaluru accounted for 4.45 billion km.

Delhi sees more night trips than Bengaluru, Mumbai, says Ola

Most Popular

Mukesh Ambani 9th richest on Forbes' real-time billionaires list
Top credit card myths harmful for your financial well-being
Microsoft CEO Satya Nadella tops Fortune's Businessperson of the Year 2019
Employment growth slowed down in last two years: report
GST structure: key challenges and its solutions

Editor's Picks

Income tax e-filers drop by over 6.6 lakh in FY19: Official data
Swiping on your smartphone reveals a lot about you to your social media company
  • Read Financial Chronicle as it appears in print.
  • Subscribe, and get it delivered in the inbox everyday.
  • Politics, Plan And Policy
  • Markets
  • Companies
  • Economy
  • In Other News
  • Autos
  • Just In
  • Home
  • About Us
  • Contact Us
  • Terms of Service
  • Privacy Guidelines
  • Copyright © 2019 Financial Chronicle, All rights reserved
Developed & Maintained By Daksham